ACXP ACXP
Company Profile ↓Company Overview
ACXP (ACXP) is a publicly traded company listed on with a market capitalization of $3.45M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -74.83% |
| 6 Months: | -35.53% |
| 3 Months: | -26.50% |
| 1 Month: | +1.38% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 81.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.18M | 2.27M | 2.03M | 1.62M | 1.72M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.12M | -2.83M | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.28M | -913.36K | -1.31M | -1.47M | -4.00M | -4.64M | -2.67M | -2.62M | -3.54M | -2.90M | -3.45M | -3.11M | -4.38M | -4.12M | -2.82M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M |
| Diluted EPS | - | - | -0.21 | -0.21 | -0.57 | -0.46 | -0.26 | -0.26 | -0.32 | -0.25 | -0.28 | -0.24 | -0.28 | -5.21 | -3.45 | -2.15 | -1.89 | -1.23 | - | -0.62 |
| R&D Expense | - | 400.74K | 659.98K | 91.91K | 95.07K | 1.13M | 818.89K | 911.69K | 1.59M | 1.02M | 1.74M | 1.35M | 1.56M | 1.83M | 1.20M | 598.80K | 524.21K | 429.69K | - | 341.47K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 12.09M | 14.58M | 14.12M | 8.09M |
| Operating Income | - | - | -12.09M | -14.58M | -14.12M | -8.09M |
| EBITDA | - | - | -12.09M | -14.58M | -14.12M | -8.09M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -12.09M | -14.58M | -14.10M | -7.97M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -4.60M | - | -12.09M | -14.58M | -14.10M | -7.97M |
| Diluted EPS | -0.74 | - | -22.40 | -23.00 | -17.45 | -5.32 |
| R&D Expense | 2.20M | 2.03M | 4.75M | 6.04M | 5.40M | 1.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 3.22M | - | 9.38M | 7.71M | 3.86M | 7.69M |
| Current Assets | - | - | 9.38M | 7.71M | 3.86M | 7.69M |
| Cash & Equivalents | - | - | 9.11M | 7.47M | 3.71M | 7.56M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 0 | 129.16K | 51.13K | 48.42K |
| Total Liabilities | 522.43K | - | 2.06M | 3.04M | 3.24M | 2.42M |
| Current Liabilities | 472.56K | - | 2.06M | 3.04M | 3.24M | 2.42M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - |
| Total Equity | 2.70M | - | 7.32M | 4.67M | 615.12K | 5.27M |
| Shares Outstanding | - | - | 581.38K | 723.41K | 851.53K | 2.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.35M | - | -7.54M | -9.80M | -10.38M | -6.79M |
| Investing Cash Flow | - | - | - | - | - | - |
| Financing Cash Flow | 4.04M | - | 3.70M | 8.16M | 6.62M | 10.64M |
| Capital Expenditure | - | - | - | - | - | - |
| Free Cash Flow | - | - | -7.54M | -9.80M | -10.38M | -6.79M |
| Net Change in Cash | - | - | -3.85M | -1.64M | -3.77M | 3.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -170.3% | - | -165.3% | -312.4% | -2,292.7% | -151.2% |
| ROCE % | - | - | -165.3% | -312.4% | -2,296.0% | -153.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACXP
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of a Type C Meeting conducted wit…
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a poster presentation entitled: Microbiome Restora…
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss i…
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its lead antibiotic candidate,…
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory development for companies develo…
ACXP — Frequently Asked Questions
What is the current share price of ACXP?
As of 2026-08-05 17:25 PDT, ACXP trades at $1.47 on NASDAQ/NYSE. Its 52-week range is $1.35 to $8.10.
What is the market capitalisation of ACXP?
ACXP has a market capitalisation of $3.45M on NASDAQ/NYSE.
What is the P/E ratio of ACXP?
ACXP trades at a trailing price-to-earnings (P/E) ratio of -0.28. Its price-to-book (P/B) ratio is 0.66.
Is ACXP a good stock to buy?
This page provides a data-driven analysis of ACXP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.